Breast Cancer

Momentum

3 papers in the last four weeks, against 2 the four weeks before. 0.0% of all new papers.

Jul 13Week of Sep 28

Latest papers 31

Oct 5, 2026cs.CV

Hybrid Cross-Modal Attention Network for Early Breast Cancer Detection in Low-Resource Clinical Settings

Breast cancer is the leading cause of cancer-related mortality among women in Sub-Saharan Africa, where delayed diagnosis results from limited radiology expertise and fragmented clinical data systems. Although deep learning models have demonstrated strong performance in mammographic analysis, most rely solely on imaging data and are trained on Western populations, limiting their applicability in African healthcare settings. This paper presents a Hybrid Cross-Modal Attention Network (HCMAN) that integrates mammogram images with structured clinical data using transformer-based cross-modal attention mechanisms. The model was developed and validated using a locally collected dataset of 2,560 mammogram images from 1,024 patients across four Ethiopian referral hospitals, with biopsy-confirmed ground truth labels. The proposed framework achieves 97.8% accuracy, 97.2% sensitivity, 98.3% specificity, and an AUC of 0.987, significantly outperforming image-only baselines. The system demonstrates robustness to low-quality images typical of resource-limited settings, with only 3.2% performance degradation compared to 8.7% for image-only models. Cross-modal attention analysis reveals clinically appropriate behavior: higher reliance on clinical features for ambiguous cases such as dense breasts and young patients. The model's lightweight architecture enables deployment on standard hospital workstations (<2 seconds inference on CPU). This work advances sustainable, context-aware AI solutions for equitable breast cancer diagnostics in Africa.
Sep 28, 2026q-bio.QM

An integrated geometric quantification and shape analysis framework for axillary lymph node metastasis in breast cancer patients

Quantitative characterization of lymph node morphology is important for assessing axillary lymph node metastasis in breast cancer. However, surfaces reconstructed from computed tomography (CT) segmentation may contain geometric and topological defects that compromise subsequent analysis, while conventional shape descriptors predominantly characterize global morphology. To address these issues, we developed an integrated framework combining topology-aware surface processing with multi-resolution spherical harmonic (SH) analysis of CT-derived axillary lymph nodes. The processing pipeline produced topology-valid genus-0 surfaces with improved mesh quality, which were then represented at multiple SH degrees and characterized using 20 predefined geometric feature families. Geometric fidelity increased with SH degree, whereas predictive performance peaked at intermediate resolutions. Preferred SH degree also differed across feature families. A family-specific mixed-resolution model achieved an AUC of 0.918, compared with 0.884 for the conventional PyRadiomics Shape14 baseline, corresponding to an improvement of 0.0344. Controlled perturbation experiments showed that higher SH degrees transmitted more fine-scale geometric variation and yielded lower stability of curvature-based predictions. Representative geometric descriptors provided interpretable characterization of metastasis-associated surface morphology. Independent validation further supported the framework's transportability: label-free replication in a multicenter lymph node cohort reproduced the family-specific resolution effects, while a labeled LIDC-IDRI lung-nodule experiment reproduced the resolution-dependent relationship between SH degree and predictive performance. Altogether, the framework provides a topology-valid basis for quantitative characterization of lymph node morphology and metastasis-associated imaging phenotypes.
Sep 22, 2026cs.CV

Foundation model embeddings capture pre-diagnostic changes on screening mammograms

Foundation model embeddings of screening mammograms may encode pre-diagnostic tissue change without task-specific adaptation. We tested whether embeddings move faster along a data-derived "cancer direction" in women later biopsied for cancer than in matched screen-negative controls, and whether this depends on pretraining domain. We studied 1,773 biopsied women (785 malignant, 988 biopsy-negative) and 1,773 matched controls, each with at least two annual screening exams before their index exam. An identical pipeline was applied to four 2D models: Mammo-CLIP (MC, out-of-distribution mammography), HOPPR (in-distribution mammography), MedImageInsight (MII, general medical imaging), and BiomedCLIP (biomedical vision-language pretraining on literature figures). Breast-level embeddings quantified longitudinal movement along the cancer direction. We compared cases and controls using a between-patient design with complementary mixed-effects analysis, and biopsied versus healthy contralateral breasts within patients. Under matched modality in MII embedding space, malignant cases drifted significantly faster than controls in the first two screening intervals preceding the index exam; biopsy-negative cases showed significance only in the first. MC differences were significant in the first interval for both biopsy groups. Within-patient comparisons showed a broadly similar pattern, with MC significance extending to the second interval in both groups and HOPPR showing significance at interval 1. BiomedCLIP showed no significant differences in either design or biopsy group. Overall, directional embedding velocity emerges as a property of clinically grounded rather than general biomedical pretraining, showing that foundation model embeddings can encode pre-diagnostic mammographic change without task-specific adaptation.
Sep 17, 2026cs.AI

FCA-Guided Counterfactual Explanations for Multi-Modal Breast Cancer Diagnosis: A Framework Achieving Perfect Validity with Emergent Sparsity

Deep learning models for multi-modal breast cancer diagnosis achieve high predictive accuracy but remain clinically unacceptable without actionable, counterfactual explanations. Attribution-based methods (LIME, SHAP) are categorically inapplicable to this purpose, as they generate no alternative instances and thus cannot be evaluated on counterfactual quality metrics. This investigation provides empirical evidence that FCA-Guided Counterfactual (FCA-CF) framework that uses a Formal Concept Analysis (FCA) concept lattice as a hard structural constraint on counterfactual search, operating over a multi-modal TCGA-BRCA dataset. We benchmark against four genuine counterfactual methods: Wachter-style CF, DiCE, FACE, and NICE, evaluated on 60 benign-predicted TCGA-BRCA instances. The FCA-CF framework achieves Validity = 1.0000 (100% of counterfactuals successfully flip the prediction), Sparsity = 2.37 features changed (best among all valid methods), and Proximity = 0.900 (normalised L2-based, matching NICE as joint best). The classifier achieves Accuracy = 0.980, F1 = 0.976, ROC-AUC = 0.9947. Ablation analysis confirms that the FCA lattice constraint is the primary sparsity driver (removing it increases sparsity by +40%, p < 0.001, Cohen's d = 0.78), while Phase C greedy refinement accounts for the largest individual contribution (+113% sparsity increase when disabled, p < 0.001, d = 5.01). FCA-guided counterfactual generation achieves a clinically important Pareto-dominant outcome; it is simultaneously the sparsest and among the most proximate of all valid methods, with perfect validity. The emergent sparsity property arising from lattice topology rather than numerical penalty terms constitutes a structurally novel contribution to the counterfactual explanation literature.
Aug 31, 2026cs.CV

TRUST: Threshold-Recalibrated Uncertainty-Safe Training for Certified Dismissal in Breast Cancer Screening

Reducing the review of clearly cancer-negative screening mammograms could lower radiologist workload without compromising cancer detection. We propose a closed-loop threshold-aware training strategy in which the dismissal threshold is recalculated during training and used to penalize cancer-positive images that approach the dismissal region. We evaluated the method on NLBS and RSNA using five controlled training configurations, with case-level assessment based on a one-sided 99% Clopper--Pearson upper bound for cancer prevalence among dismissed cases. The proposed model achieved the highest case-level dismissal rates at both 98% and 95% recall targets. On NLBS, dismissal reached 19.74% and 21.70%, while the cross-entropy baseline did not meet either recall target. On RSNA, dismissal improved from 7.04% to 14.31% and from 13.49% to 19.69%. In external RSNA→\toNLBS evaluation, the proposed model achieved dismissal rates of 12.95% and 19.87% at the 98% and 95% recall targets, respectively. These results support closed-loop threshold-aware training for high-recall selective dismissal.
Aug 22, 2026cs.AI

Development and Feasibility Evaluation of an Edge AI as Medical Device System for Breast Cancer Multidisciplinary Team Meetings

Breast Cancer Multidisciplinary Team (MDT) meetings manage increasingly complex cases under considerable time pressure, and documentation requirements can reduce clinical efficiency and decision quality. Existing AI based MDT workflows rely on cloud-based processing, limiting their use because patient discussions contain identifiable information. We developed a fully on-device AI pipeline using open-source Automatic Speech Recognition (ASR) and Large Language Models (LLMs) that transcribes breast cancer MDT discussions, structures clinical information, and generates treatment recommendations using retrieval-augmented generation (RAG) grounded in National Institute for Health and Care Excellence (NICE) guidance. The pipeline runs on a single NVIDIA Jetson AGX Orin, ensuring that patient audio, transcripts, and outputs remain within institutional infrastructure. Evaluation included two recorded simulated MDT discussions, ten clinically validated synthetic discussions, and 1,270 acoustically augmented recordings. Optimisation of Whisper large-v3 reduced word error rate by 20.7% and 24.4% on the recorded discussions and achieved performance within 0.58% WER and 1.58% word information lost of a commercial clinical ASR benchmark on augmented audio. MedGemma-RAG identified 2.3 times more MDT-concordant interventions than a proprietary cloud comparator (p = 0.020), with no significant difference in overall accuracy. Stakeholders identified automated documentation, treatment recommendation support, and case triage as the most credible near-term applications while highlighting workflow integration, governance, and clinician trust as key implementation challenges. These findings demonstrate the feasibility of privacy-preserving, fully on-device AI for MDT documentation and guideline-informed decision support, providing a foundation for prospective clinical evaluation.
Aug 7, 2026eess.IV

Energy and Performance Benchmarking of Deep Learning Models for Breast Cancer Detection

Recent advances in machine learning have greatly improved breast cancer detection, enabling more accurate and timely diagnosis. Deep learning (DL) models show strong potential for medical image analysis; however, as their architectural complexity increases, their environmental impacts are becoming a growing concern. In this paper, we present a comparative analysis of seven DL models for breast cancer detection on two medical datasets: Breast Ultrasound and BreakHis 400X. The evaluated architectures range from Convolutional Neural Networks (CNNs) and transformers to hybrid models. In addition to performance metrics, we assess CO2 emissions during both training and inference. Our results show that EfficientNet and ResNet consistently deliver strong performance, although with higher CO2 emissions. The selected transformers, such as DeiT-Tiny, perform competitively on both datasets, whereas DenseNet121 achieves lower accuracy. On the Breast Ultrasound Dataset, DeiT provides the most favourable balance between accuracy and energy consumption, whereas on the BreakHis dataset, the ViT and Swin models achieve the best results. Overall, our findings indicate that no single architecture category from the evaluated ones consistently dominates across the two selected datasets. Our results highlight the importance of jointly considering performance, emissions, and dataset characteristics when selecting models for medical applications.
Aug 7, 2026eess.IV

Longitudinal 3D Foundation Modeling for Neoadjuvant Breast Cancer Response Prediction from Serial DCE-MRI

Pathologic complete response (pCR) is an important endpoint in neoadjuvant chemotherapy (NAC) for breast cancer, and predicting pCR from imaging during treatment could support treatment response assessment. Many existing imaging-based approaches rely on a single static timepoint, which fails to capture changes that occur during treatment. In this work, we present a longitudinal framework that combines a frozen 3D foundation encoder (Pillar-0) with our Temporal Dynamics Network (TDN) to predict treatment response from serial Dynamic Contrast-Enhanced (DCE) MRI acquired across four clinical timepoints from pre-treatment to pre-surgery. The TDN combines time-aware volumetric embeddings with clinical and treatment data to predict pCR. Evaluated on 982 patients from the combined I-SPY2 and ACRIN-6698 cohort, the proposed model achieves strong performance across all reported metrics when longitudinal 3D imaging is fused with clinical data (test AUROC: 73.6%, balanced accuracy: 69.1%). While clinical variables provide the strongest individual predictive signal, longitudinal 3D imaging contributes complementary information when fused with clinical data, improving pCR prediction. Our source code is available at: https://github.com/omarftt/longitudinal_temporal_pillar.
Aug 4, 2026cs.AI

Spatial proteomics guided by H&E-based AI reveals recurrence-risk niches in triple-negative breast cancer

Deep learning models can predict cancer recurrence from H&E stained slides, but the localized molecular states underlying these predictions remain largely obscured. Here, we developed an outcome informed spatial pathology framework in TNBC that integrates AI generated recurrence risk heatmaps with mass spectrometry based spatial proteomics. In a cohort of 156 patients, distribution based aggregation of high scoring patches achieved an AUC of 0.77 and a C-index of 0.77 in an independent test cohort. Bulk proteomics associated high image derived risk with cell cycle and genome maintenance programs and low risk with immune activation. High and low risk patches coexisted within the same tumor compartment and displayed distinct nuclear and architectural features, revealing intratumoral heterogeneity beyond tissue compartment identity. We then used the heatmaps as coordinate level guides to physically isolate and profile 46 AI defined tumor regions from two recurrence patients. Spatial proteomic profiling revealed a concordant molecular contrast across both patients: mitotic programs were enriched in high risk regions and immune and antigen presentation programs in low risk regions. A 13 protein composite derived from these spatial contrasts showed a trend toward poorer recurrence-free survival with increasing scores in an expanded cohort, while the corresponding transcript based composite stratified recurrence free survival in the independent METABRIC TNBC cohort. Integrating the protein composite with the H&E derived risk score improved the out of bag C-index from 0.679 to 0.739 and enhanced time dependent discrimination at 3 and 5 years. Together, these findings define a new role for outcome trained AI models as spatially explicit experimental guides that connect prognostic morphology with localized molecular states and advance biologically grounded, multiscale biomarker discovery in TNBC.
Aug 4, 2026cs.CV

CorePath: A Breast-Specialized Pathology Foundation Model for Core Needle Biopsy Diagnosis and Risk-Controlled Report Generation

Breast core needle biopsy (CNB) is central to breast cancer diagnosis yet remains challenging because limited tissue sampling, lesion heterogeneity, and subtle morphologic overlap can obscure subtype distinctions. We developed CorePath, a breast-specialized multimodal pathology foundation model fine-tuned from PRISM using 7901 paired CNB whole-slide images and diagnostic reports from two centers. Evaluated across six CNB cohorts and two public breast pathology benchmarks without task-specific retraining, CorePath consistently outperformed PRISM across cancer detection, invasion assessment, and histological subtyping. It achieved weighted area under the receiver operating characteristic curves (AUCs) of 0.9526-0.9735 for five-class CNB histological subtyping across private centers. On public benchmarks, CorePath outperformed leading pathology foundation models, achieving the highest weighted AUCs of 0.7780 for BCNB invasive carcinoma subtyping, 0.8178 for BRACS lesion stratification, and 0.8252 for BRACS fine-grained classification. In report generation, CorePath reduced the overall non-breast hallucinations from 30.1% to 2.8%, demonstrating improved domain fidelity after breast-specific adaptation. CorePath-CRG further combined conformal filtering of subtype and binary cancer status predictions with Learn-Then-Test-based threshold calibration to support selective narrative release, diagnostic fallback, and deferral. CorePath-CRG achieved zero non-breast hallucinations among released outputs and showed the strongest overall performance in pathologist-validated LLM-based Evaluation Scores and quantitative report-generation metrics across most centers. These results demonstrate that domain-specialized foundation models with statistical risk control offer a promising approach for accurate breast CNB diagnosis and reliable report generation.
Jul 31, 2026cs.CV

What Carries the Signal in Pathology Foundation-Model Atlases? A Patient-Level Controlled Benchmark in Breast Cancer

Pathology foundation models are reported to encode molecular programmes in tissue morphology, but the evidence is usually a cohort-wide ranked gene list rather than a prediction for a held-out patient. We rebuild such an analysis with the patient as the unit of evidence and ask which pipeline component carries signal. Across 11 frozen backbones, four pre-specified gene programmes and 285 TCGA-BRCA patients with paired slides and RNA-seq (44 cells; GroupKFold by patient, all preprocessing fitted inside the fold), ridge regression on mean-pooled embeddings predicts held-out programme scores at Spearman rho = 0.25-0.56, UNI2 strongest on all four (immune 0.556). A matched permutation null gives raw p ~ 1e-4 at 10,000 permutations for every cell; Holm-adjusted p = 0.0044. The signal is real but not uniformly morphological. Against competing models on the same patients and folds, embeddings beat tissue composition for ER/luminal, proliferation and immune (+0.280, +0.284, +0.479; p <= 0.003) but not basal, where compartment fractions alone reach 0.469 against the embedding's 0.493 (p = 0.77). Fifty-four interpretable cell-count features come within 0.043-0.085 on every programme. The geometric machinery contributes nothing measurable, and we identify why: the geodesic graph selects neighbours by Euclidean nearest-neighbour search and only reweights edges already chosen, so the topology is Euclidean by construction (Riemannian minus Euclidean = +0.0010, 95% CI [-0.0007, +0.0029]). Applied consistently the geometry is worse (-0.0117). Ridge regression beats the graph-and-metric decoder by +0.097 (CI [+0.069, +0.127]). The driver-count metric common in this literature is near-uninformative here: 91.8% of random six-gene panels recover >=5/6 drivers.
Jul 21, 2026cs.LG

Trustworthy Privacy-Preserving Multimodal Federated Learning for Personalised Breast Cancer Prediction

Federated learning has emerged as a potential solution to privacy concerns associated with using sensitive health data for training predictive models, particularly in personalised cancer care. This research investigates whether federated learning can support the development of robust models for predicting tumour progression in breast cancer patients while addressing four critical deployment pillars: transparency, scalability, security, and fairness. This study evaluates a federated learning framework using multimodal data, including clinical information, tumour characteristics, biomarker data, and patient demographics, alongside medical imaging data such as MRI scans, to model changes in tumour characteristics over time. The performance of the federated approach was compared with that of a centralised model trained on aggregated data. The report then further examines strategies to enhance secure model updates, maintain performance across patient subgroups, and support scalability across institutions. The findings assess whether federated learning can achieve predictive performance comparable to centralised learning while preserving data locality. These results contribute to understanding the feasibility of privacy-preserving, multimodal predictive modelling and support future applications such as digital twins to assist clinicians and patients in personalised treatment planning.
Jul 21, 2026cs.LG

An unsupervised clustering analysis of breast cancer data derived from electronic health records enhanced through UMAP dimensionality reduction

Breast cancer is one of the most widespread types of cancer, affecting approximately 8 million women worldwide. Electronic health records of patients diagnosed with this disease can serve as valuable datasets for computational analyses, enabling the discovery of new insights about the pathology. Unsupervised clustering, in particular, can identify groups of patients with medically significant features, revealing data trends that might otherwise go unnoticed by medical doctors. In this study, we first applied the DBSCAN density-based clustering method to three independent datasets derived from electronic medical records of patients with mammary carcinoma. Subsequently, to enhance our results, we preceded the DBSCAN application with a dimensionality reduction phase using UMAP. We evaluated our clustering outcomes using three statistical indices (DBCV, DCSI, and DISCO). Our results confirm the effectiveness of combining UMAP with DBSCAN for clustering data derived from electronic health records, paving the way for the medical interpretation of the patient groups identified by our approach.
Jul 13, 2026cs.CV

Longitudinal Multi-View Breast Cancer Risk Prediction

Accurate breast cancer risk prediction from screening mammography is critical for enabling personalized screening intervals and early detection. Recent deep learning methods have shown the value of longitudinal data and explicit temporal alignment. However, existing approaches either perform explicit alignment using a single mammographic view or model multiple views without explicit longitudinal alignment, limiting their ability to exploit the complementary spatial-temporal information used in clinical practice. To address this gap, we propose LMV-Net, a longitudinal multi-view breast cancer risk prediction model that jointly analyzes anatomically complementary CC and MLO views within an explicitly aligned longitudinal framework. We evaluate our approach on the public EMBED and CSAW-CC datasets, comparing it to state-of-the-art breast cancer risk prediction methods. Our model consistently outperforms existing approaches in overall risk prediction performance and across different breast density and cancer subgroups. Importantly, these improvements highlight the potential of longitudinal multi-view modeling to enhance risk stratification, paving the way for future work on personalized screening, earlier identification of high-risk patients, and more efficient screening resource allocation. The code is available at https://github.com/sot176/LMV-Net.
Jul 2, 2026eess.IV

Pretreatment MRI reveals a latent, molecular-subtype-independent structural phenotype that organizes treatment trajectories and recurrence risk

Pathologic complete response and tumor shrinkage measure whether breast cancer responds to neoadjuvant therapy, but not whether that response was structurally favorable, persistent, or hidden beneath volume loss. We built an outcome-blind longitudinal DCE-MRI manifold from I-SPY2 trajectories to test whether pretreatment imaging carries a structural response phenotype missed by conventional descriptors. The dominant axis of response geometry was not recoverable from the full clinical and genomic stack -- age, receptor subtype, MammaPrint, PAM50, treatment arm, and tumor burden -- but became strongly recoverable once baseline structural entropy was added. A constrained representation mapping recovered the same axes as unconstrained decomposition, establishing the structure as intrinsic rather than a post-hoc interpretation. The phenotype persisted through therapy, and as treatment proceeded the volumetric signal faded while entropy stayed separated -- a crossover from burden to structural persistence. Among complete responders, structurally disordered tumors could shrink more early yet remain structurally disordered, a volumetric deception invisible to endpoint labels. External analyses in UCSF, I-SPY1, and Duke established recurrence relevance under representation-dependent boundaries, and a representation-family commensurability assessment showed why feature-name matching is insufficient: the same label can fail, transport, or entangle with extraction geometry. Pretreatment MRI therefore exposes a structural response phenotype that endpoint-based language leaves invisible -- including, among complete responders, a pretreatment imaging signal of structurally distinct response states that awaits prospective validation.
Jun 30, 2026cs.CV

AEGIS: A Multi-Task Joint-Embedding Predictive Architecture for Mammography

We present Aegis, a joint-embedding predictive architecture for breast cancer detection and density assessment in mammography. We train three Vision Transformer variants (Small/Base/Large) using self-supervised joint-embedding predictive architecture (JEPA) pre-training on 71,103 studies from 14 clinical sites, followed by supervised fine-tuning with progressive resolution scaling up to 2048x1536. On a curated 785-study test set, our largest model achieves area under the receiver operating characteristic curve (AUC) 0.949 for breast cancer triage with 93% sensitivity and 75% specificity at the optimal operating point. An ensemble combining our model with a U.S. Food and Drug Administration-cleared baseline further improves discrimination to 0.952 AUC. For breast density classification, the model achieves 0.953 AUC for binary (dense vs. non-dense) classification and 62.6% exact accuracy across four Breast Imaging Reporting and Data System (BI-RADS) categories, with 98.8% adjacent accuracy comparable to reported human inter-reader agreement. External validation on the public VinDr-Mammo dataset provides evidence of cross-population transfer under a different reference standard, with the largest model achieving 0.871 AUC for triage in a zero-shot setting.
Jun 29, 2026cs.CV

Latent-CURE for Breast Cancer Diagnosis

Multimodal Large Models have significantly advanced automated breast ultrasound diagnosis. However, most existing frameworks utilize opaque, end-to-end paradigms prioritizing global statistical correlations over structured clinical reasoning. Consequently, these models remain susceptible to shortcut learning amid extreme real-world epidemiological imbalances, often bypassing rare but decisive malignant indicators for dominant benign patterns. To address this disconnect, we propose Latent-CURE, a novel diagnostic framework driven by asymmetric weighted chain-of-thought methodology grounded in latent space reasoning. Unlike traditional approaches, our framework constructs an implicit reasoning trajectory forcing the model to sequentially infer standardized BI-RADS morphological descriptors before converging on a final diagnosis. Furthermore, to combat the extreme scarcity of critical malignant features, we couple this architecture with a dual-asymmetric optimization strategy. By dynamically adjusting margins and weights, this strategy safeguards high-specificity malignant descriptors from being overshadowed by common benign priors. Comprehensive evaluations demonstrate that our knowledge-injected approach provides transparent clinical evidence while achieving robust, accurate diagnostic performance in imbalanced medical cohorts.
Jun 24, 2026eess.IV

Revealing Mammographic Phenotypes in Deep Learning Breast Cancer Risk Models

Mammogram-based deep learning models have improved breast cancer risk prediction, but the learned imaging patterns remain underexplored. Existing interpretability methods rely on single-image saliency maps, failing to identify recurring mammographic phenotypes across large patient cohorts. By clustering patch embeddings from a pre-trained model, Mirai, we isolate recurring phenotypes linked to 5-year cancer risk. Analyses show risk-increasing phenotypes capture complex structures (e.g., dense tissue, microcalcifications) and shortcut artifacts (e.g., clips). These phenotypes correlate strongly with older age and higher BI-RADS density. Our framework connects tissue patterns to AI risk scores, revealing clinical signatures and potential latent model confounders.
Jun 19, 2026cs.CV

HERO: Hypothesis-Driven Evidence Retrieval from Omics for Multi-Task Breast Cancer Analysis

Matched multi-omics can improve WSI-based biomarker and prognosis prediction, but most existing pipelines use omics as a paral lel feature stream or textual context rather than as an explicit retrieval constraint. HERO asks whether observed omics can be a testable mor phology hypothesis: a sparse pathway-to-morphology prior maps DNA methylation and miRNA into a K-dimensional intent vector m (K=16), TF-IDF retrieval over structured 10 captions selects endpoint-relevant regions, and a cosine gate c=cos(m,v) triggers deterministic deficit driven repair when c<τc. This closed-loop design bounds VLM calls, reduces reliance on embedding-based semantic matching, and makes every retrieval and verification step lexically auditable. On TCGA-BRCA (930WSIs, patient-level 5-fold CV), HERO sets new state-of-the-art across ER, PR, HER2, subtype, and risk prediction, outperforming both multimodal fusion and VLM-based baselines.
Jun 12, 2026cs.CV

A Lightweight Fiducial-Based Pipeline for 3D Hyperspectral Mapping of ex-vivo Lumpectomy Specimens

Hyperspectral Imaging (HSI) is a promising modality for intraoperative assessment of resection margins in Breast-Conserving Surgery (BCS), but its clinical translation requires aligning the inherently 2D spectral information onto the 3D shape of the excised tissue so that suspicious regions can be precisely localized for targeted follow-up. We present a fully automated, calibration-free pipeline that produces a 3D hyperspectral point cloud of an ex-vivo lumpectomy specimen from a set of consumer-camera RGB images and a single top-down HSI acquisition. The 3D geometry is reconstructed with a deep-learning Structure-from-Motion backbone, stabilized in a metric reference frame by a custom bundle adjustment that enforces consistency on the corners of four ArUco markers placed around the specimen. The HSI cube is then registered to the reconstruction without recovering the HSI camera pose: the markers, visible in both modalities, define 16 corner correspondences that drive a planar homography, and 3D coordinates are recovered by lookup on an orthographically rendered depth map. Evaluated on two ex-vivo lumpectomy specimens, the pipeline achieves a median 3D registration error below 1~mm and a 2D reprojection error below 0.02 mm, with a total per-specimen processing time under 4 minutes on accelerated hardware. These results support the feasibility of integrating HSI-guided spatial localization into intraoperative margin assessment workflows for breast-conserving surgery.
Jun 10, 2026q-bio.QM

Seeing Below the Limit of Detection: A Censored-Poisson Bayesian Latent-Growth Change-Point Detector (the Span Detector) for Serial ctDNA in HR+/HER2- Metastatic Breast Cancer

Circulating-tumour DNA (ctDNA) carries evidence of drug resistance months before imaging shows it, but the earliest evidence lives below the assay's limit of detection (LoD): a nascent subclone is detected only intermittently, producing a flickering sequence of faint detects and non-detects. Commercial liquid biopsies treat each draw as an independent snapshot and a non-detect as nothing. We argue a non-detect is a left-censored observation, and the pattern of non-detects and faint detects over time carries actionable evidence of growth before any single value is trustworthy. We introduce Span, a censored-Poisson Bayesian latent-growth change-point detector that models the binary detection process, accumulates a sequential generalised-likelihood-ratio statistic for an upward change-point in the per-variant detection rate, and raises a competing-risks alarm with calibrated false-alarm control. Span has no learned weights, so there is nothing to overfit. On a synthetic cohort of HR+/HER2- metastatic breast cancer on first-line CDK4/6-inhibitor plus endocrine therapy, at a matched 10% false-alarm rate, Span roughly doubles the fraction of impending progressions caught three months ahead (indolent regime: 25% vs 11% for the snapshot), with a falsifiable dose-response: large for indolent emergence, vanishing for fast emergence. A value-trajectory baseline performs identically to the snapshot, isolating the gain to the censored detection model. The survival backbone matches a Cox baseline on real breast-cancer data (GBSG-2, n=686; C-index 0.67 vs 0.68), and on a real longitudinal cohort with clean biomarkers (PBC2, n=312) the same pipeline correctly declines to win, a falsifiable boundary test confirming the mechanism is regime-specific. All ctDNA trajectories are synthetic.
Jun 3, 2026cs.CV

BreastGPT: A Multimodal Large Language Model for the Full Spectrum of Breast Cancer Clinical Routine

Breast cancer remains a leading cause of cancer-related mortality among women. Its clinical management requires multimodal reasoning across a clinical workflow that spans \textit{screening}, \textit{diagnosis} and \textit{treatment planning}, where each stage involves distinct imaging modalities, task objectives, and reasoning patterns. However, constrained by data scarcity and model versatility, existing medical MLLMs are typically evaluated on isolated modalities or narrow task families, limiting their ability to support workflow-level clinical reasoning. In this work, we first introduce \textbf{BreastStage}, a workflow-aligned breast imaging instruction corpus comprising 1.86M instruction-following pairs curated from 17 sub-datasets across 5 imaging modalities and 136 task templates. Its held-out split, \textbf{BreastStage-Bench}, provides a comprehensive benchmark for evaluating multimodal reasoning across the breast cancer care continuum. Building on this corpus, we propose \textbf{BreastGPT}, a unified MLLM equipped with a dual-branch visual encoder and concept-preserving token compression to bridge the scale gap between standard radiology and gigapixel pathology. On BreastStage-Bench, BreastGPT achieves 75.66% closed-ended accuracy and 89.92% open-ended score, outperforming both general-purpose and medical-specific MLLMs across clinical stages and task formats. These results suggest that workflow-aligned data and cross-scale visual modeling are critical for clinically grounded medical MLLMs. All data, code, and model checkpoints are released at https://yangyy-liu.github.io/BreastGPT.io.
Jun 1, 2026cs.LG

Multi-Modal Machine Learning for Breast Cancer Recurrence Prediction

Breast cancer recurrence, a leading cause of long-term mortality among survivors, requires timely and accurate risk assessment to guide follow-up care and treatment planning. Traditional predictive models, often limited to either structured or unstructured data alone, struggle to capture the full clinical context. This study examines the impact of integrating multi-modal clinical data, including treatment records, pathology reports, and clinician notes, on recurrence prediction. By integrating a rule-based regular expression extraction mechanism with a rigorous precedence-based conflict reconciliation strategy, our approach effectively recovers definitive tumor characteristics from free-text pathology narratives to augment structured records. We also benchmark performance against commonly used feature sets from prior breast cancer studies to assess the added value of multi-modal integration. Single-source and multi-modal inputs are evaluated across a range of machine learning models. Results show that multi-modal integration consistently improves predictive accuracy compared to single-modal methods.
May 8, 2026cs.CL

Can Language Models Identify Side Effects of Breast Cancer Radiation Treatments?

Accurately communicating the side effects of cancer treatments to cancer survivors is critical, particularly in settings such as informed consent, where clinicians must clearly and comprehensively convey potential treatment toxicities. However, this task remains challenging due to clinical knowledge deficits about adverse treatment effects and fragmentation across electronic health record (EHR) systems. Large language models (LLMs) have the potential to assist in this task, though their reliability in oncology survivorship contexts remains poorly understood. We present a deployment-oriented stress-testing framework for evaluating LLM-generated radiation side effect lists in breast cancer treatment and survivorship care. Using 21 breast cancer patient profiles, we construct paired patient clinical scenarios that differ only in radiotherapy regimens to evaluate seven instruction-tuned LLMs under multiple prompting regimes. We then compare LLM outputs to a clinician-curated reference derived from informed consent documents at two major academic medical centers and developed by a team including more than seven breast radiation oncologists. The reference maps radiation dose-fractionation, fields, and locations to associated toxicities, broken down by frequency and temporal onset. Across models, we reveal sensitivity to minor documentation changes, trade-offs between precision and recall, and systematic under-recall of rare and long-term side effects. When used alone, constraints on the number of side effects generated reduce precision, and grounding outputs in clinician-curated side effect lists substantially improves reliability and robustness. These findings highlight important limitations of LLM use in oncology and suggest practical design choices for safer and more informative survivorship-focused applications.
May 8, 2026cs.CV

Multimodal Stepwise Clinically-Guided Attention Learning for Pathological Complete Response Prediction in Breast Cancer

Pathological complete response (pCR) is a key prognostic factor in breast cancer patients undergoing neoadjuvant therapy, strongly associated with long-term survival and treatment personalization. However, accurate pre-treatment pCR prediction remains challenging due to severe class imbalance and limited generalizability across diverse clinical settings. In this work, we propose a multimodal stepwise clinically-guided attention learning framework for pCR prediction from breast magnetic resonance imaging (MRI), designed to address these limitations through medically grounded spatial guidance and multimodal integration. The approach follows a stepwise training strategy inspired by physician reasoning: the model first learns global discriminative imaging patterns, then attention mechanisms are introduced to constrain the network toward tumor regions, and finally clinical variables are integrated to refine decision-making. This guidance strategy encourages prioritization of task-relevant features, improving identification of responders despite their limited representation in the dataset. Moreover, grounding attention in anatomically consistent tumor regions reduces reliance on dataset-specific patterns, thereby enhancing cross-institutional generalization. The framework is evaluated through external validation across heterogeneous MRI cohorts. Compared to non-guided single-stage baselines, the proposed approach improves sensitivity while maintaining competitive specificity, and produces anatomically coherent attention maps that support interpretation of the model's predictions. These findings highlight the potential of clinically-guided multimodal attention learning for robust and generalizable pCR prediction in breast cancer.
May 7, 2026cs.LG

Feature Dimensionality Outweighs Model Complexity in Breast Cancer Subtype Classification Using TCGA-BRCA Gene Expression Data

Accurate classification of breast cancer subtypes from gene expression data is critical for diagnosis and treatment selection. However, such datasets are characterized by high dimensionality and limited sample size, posing challenges for machine learning models. In this study, we evaluate the impact of model complexity and feature selection on subtype classification performance using TCGA-BRCA gene expression data. Logistic regression, random forest, and support vector machine (SVM) models were trained using varying numbers of highly variable genes (50 to 20,518). Performance was evaluated using stratified 5-fold cross-validation and assessed with accuracy and macro F1 score. While all models achieved high accuracy, macro F1 analysis revealed substantial differences in subtype-level performance. Logistic regression demonstrated the most stable and balanced performance across subtypes, including improved detection of rare classes. Random forest underperformed on minority subtypes despite strong overall accuracy, while SVM showed sensitivity to feature dimensionality. These findings highlight the importance of model simplicity, evaluation metrics, and feature selection in high-dimensional biological classification tasks.
Apr 26, 2026cs.CV

Mammographic Lesion Segmentation with Lightweight Models: A Comparative Study

Breast cancer is a leading cause of cancer-related mortality among women worldwide, with mammography as the primary screening tool. While deep learning models have shown strong performance in lesion segmentation, most rely on computationally intensive architectures that limit their use in resource-constrained environments. This study evaluates the performance and efficiency of lightweight models for mammographic lesion segmentation. Architectures including MobileNetV2, EfficientNet Lite, FPN, and Fast-SCNN were compared against a U-Net baseline using the INbreast dataset with 5-fold cross-validation. Performance was assessed using Dice score, Intersection over Union (IoU), and Recall, alongside model complexity. MobileNetV2 with Squeeze-and-Excitation (SCSE) achieved the best performance, with a Dice score of 0.5766 while using approximately 75% fewer parameters than U-Net. Cross-dataset evaluation on the DMID dataset showed reduced accuracy due to domain shift but preserved recall. These results demonstrate that lightweight architectures offer a practical balance between performance and efficiency for deployable CAD systems.
Apr 18, 2026cs.CV

Multimodal Fusion of Histopathology Images and Electronic Health Records for Early Breast Cancer Diagnosis

Breast cancer is a leading cause of cancer-related mortality worldwide, and timely accurate diagnosis is critical to improving survival outcomes. While convolutional neural networks (CNNs) have demonstrated strong performance on histopathology image classification, and machine learning models on structured electronic health records (EHR) have shown utility for clinical risk stratification, most existing work treats these modalities in isolation. This paper presents a systematic multimodal framework that integrates patch-level histopathology features from the BreCaHAD dataset with structured clinical data from MIMIC-IV. We train and evaluate unimodal image models (a simple CNN baseline and ResNet-18 with transfer learning), unimodal tabular models (XGBoost and a multilayer perceptron), and an intermediate-fusion model that concatenates latent representations from both modalities. ResNet-18 achieves near-perfect accuracy (1.000) and AUC (1.000) on three-class patch-level classification, while XGBoost achieves 98% accuracy on the EHR prediction task. The intermediate fusion model yields a macro-average AUC of 0.997, outperforming all unimodal baselines and delivering the largest improvements on the diagnostically critical but class-imbalanced mitosis category (AUC 0.994). Grad-CAM and SHAP interpretability analyses validate that model decisions align with established pathological and clinical criteria. Our results demonstrate that multimodal integration delivers meaningful improvements in both predictive performance and clinical transparency.
Mar 3, 2026cs.CV

BRIGHT: A Collaborative Generalist-Specialist Foundation Model for Breast Pathology

Generalist pathology foundation models (PFMs), pretrained on large-scale multi-organ datasets, have demonstrated remarkable predictive capabilities across diverse clinical applications. However, their proficiency on the full spectrum of clinically essential tasks within a specific organ system remains an open question due to the lack of large-scale validation cohorts for a single organ as well as the absence of a tailored training paradigm that can effectively translate broad histomorphological knowledge into the organ-specific expertise required for specialist-level interpretation. In this study, we propose BRIGHT, the first PFM specifically designed for breast pathology, trained on over 51,000 breast whole-slide images derived from a cohort of over 40,000 patients across 19 hospitals. BRIGHT employs a collaborative generalist-specialist framework to capture both universal and organ-specific features. To comprehensively evaluate the performance of PFMs on breast oncology, we curate the largest multi-institutional cohorts to date for downstream task development and evaluation, comprising over 25,000 WSIs across 10 hospitals. The validation cohorts cover the full spectrum of breast pathology across 25 distinct clinical tasks spanning diagnosis, biomarker prediction, treatment response and survival prediction. Extensive experiments demonstrate that BRIGHT outperforms five leading generalist PFMs, achieving state-of-the-art (SOTA) performance in 25 of 25 internal validation tasks and in 4 of 11 external validation tasks with excellent heatmap interpretability. By evaluating on large-scale validation cohorts, this study not only demonstrates BRIGHT's clinical utility in breast oncology but also validates a collaborative generalist-specialist paradigm, providing a scalable template for developing PFMs on a specific organ system, accelerating the translation of foundation models into ...
Nov 24, 2025cs.CV

OncoVision: Integrating Mammography and Clinical Data through Attention-Driven Multimodal AI for Enhanced Breast Cancer Diagnosis

OncoVision is a privileged-information training framework that uses mammography images and clinical features during training and performs inference from mammographic images alone. Employing an attention-based encoder-decoder backbone, it jointly segments four regions of interest (masses, calcifications, axillary findings, and breast tissue) with accuracy exceeding the nnU-Net baseline and predicts ten structured clinical features, including BI-RADS category. We developed two late-fusion strategies, Independent and Dependent, that integrate imaging, radiomic, and clinical information during training to improve diagnostic precision and potentially reduce inter-observer variability. Radiomic features extracted from predicted masks provide shape, intensity, and texture descriptors that complement the learned CNN representations. We evaluated OncoVision in a retrospective multi-reader study with six board-certified radiologists, assessing diagnostic confidence, reading time, and segmentation accuracy with and without AI assistance. In a paired reader-assistance evaluation, OncoVision was associated with higher diagnostic confidence for junior and senior radiologists, reduced reading time by up to 61%, and achieved segmentation accuracy comparable to or exceeding that of radiologists for mass lesions. We operationalized OncoVision as a secure web application, now deployed at a partner hospital, that generates structured reports with dual-confidence scoring and attention-weighted visualizations for real-time diagnostic support. The platform is designed for integration into clinical workflows, with the goal of supporting screening access in underprivileged regions. By combining accurate segmentation with clinical intuition, OncoVision advances AI-assisted mammographic interpretation, offering a scalable and accessible approach to earlier and more consistent image interpretation.
Date pendingcs.LG

Longitudinal Risk Prediction in Mammography with Privileged History Distillation

Longitudinal mammography screening has become an important source of information for improving future breast cancer risk prediction. However, the performance of current longitudinal mammography models degrades when prior examinations are unavailable at inference, creating a structured privileged-information setting in which temporal context is available during training but absent at deployment. We propose Single-Exam Mammography risk prediction with privileged History Distillation (SEM-HD), a framework that uses longitudinal history as privileged information available only during training to preserve the predictive benefits of longitudinal modeling while requiring only the current screening examination at deployment. During training, the student relies on the current examination to predict latent representations of prior visits, while horizon-specific teachers provide additional supervision from the observed longitudinal history. Together, latent history prediction and teacher distillation preserve the temporal modeling structure of longitudinal predictors under current-exam-only inference. We validate SEM-HD on three longitudinal mammography cohorts, the CSAW-CC, EMBED, and OMI-DB, using the transformer-based Longitudinal Mammography Risk (LoMaR) and recurrent Visual Memory Recurrent Attention (VMRA) backbones. Under current-exam-only inference, SEM-HD consistently improves long-horizon AUC and pAUC over longitudinal models evaluated without history, particularly in the clinically relevant low false-positive-rate region. It also recovers much of the performance gap with respect to full-history inference across datasets and backbones. Ablations further show that these gains are not reproduced by masking or heuristic history imputation. The strongest performance is achieved by combining patient-specific latent history prediction with distilled temporal risk supervision.